Acyclovir: profile and news

Deconstructing Myogen's market cap  07 Mar 2006
They found it superior to PAH market-leader Actelion's Tracleer (bosentan), which generated revenue for Actelion of $350 million in the first nine months of ... - Nature.com (subscription),

Pfizer launches Revatio in UK for lung disease  07 Mar 2006
Switzerland's Actelion currently makes the leading product for the condition, but its Tracleer medicine faces growing competition from Revatio and other rivals ... - Reuters.uk,

Actelion dips as Glaxo bolsters rival drug  07 Mar 2006
...will be the third drug to market to treat pulmonary arterial hypertension, a rare form of lung disease whose treatment is dominated by Actelion's Tracleer. ... - Reuters

FDA MedWatch - Tracleer (Bosentan): Recommended Dosage Adjustment ...  Mar 2, 2006
BETHESDA, MD -- March 2, 2006 -- Actelion and FDA notified healthcare professionals of changes to the Tracleer (bosentan) prescribing information based on ... - DG News

Actelion 2005 profit rises 44 pct, Tracleer shines  Feb 22, 2006
...rose 44 percent to 125.5 million Swiss francs ($95.87 million) in 2005, at the lower end of market expectations, as sales of its key Tracleer drug continued to ... - Reuters

UPDATE 2-Actelion 2005 profit rises 44 pct, Tracleer shines  Feb 22, 2006
Actelion (ATLN.S: Quote, Profile, Research) rose 44 percent in 2005, at the lower end of market expectations, as sales of its key Tracleer drug continued to ... - Reuters

FDA and Actelion Pharmaceuticals Issue ‘Reminder’ of ...  Mar 3, 2006
The notification underscored the need to continue monthly liver function monitoring for the duration of Tracleer treatment and the need to adhere to the ... - Newsinferno.com,

UPDATE 1-New liver damage info added to Actelion drug label  Mar 2, 2006
2 (Reuters) - New information about rare cases of liver damage has been added to the label of Actelion's (ATLN.S: Quote, Profile, Research) Tracleer lung drug ... - Reuters

Actelion "Dear Doctor" Letter No Problem -GS  Mar 3, 2006
1118 GMT [Dow Jones] Actelion's (ATLN.EB) "dear doctor" letter highlighting the case of a severe liver failure probably related to its drug Tracleer isn't an ... - New Ratings

(PZ) Actelion Announces Full Year 2005 Financial Results  Feb 22, 2006
Executive Officer commented: "In 2005, our educational efforts resulted in a rapidly expanding PAH market, with consequently outstanding Tracleer(r) sales ... - Houston Chronicle,

Swiss pharma Actelion's profit rises 5%, sales gain 44%  Feb 23, 2006
...based in Allschwil, Switzerland, said sales rose to CHF186.5 million from CHF130 million the previous year, driven by demand for its flagship drug Tracleer. ... - MarketWatch

JP Morgan Starts Actelion At Overweight  Feb 28, 2006
...consider the company to be truly innovative, meaning it would be valued at biotech multiples, or whether they think its core product, Tracleer, was just a ... - New Ratings

Actelion Rebounds From Thu 'Over-Reaction'  Mar 3, 2006
0857 GMT [Dow Jones]--Actelion (ATLN.EB) +5.1% at CHF113.6, grabbing back ground lost Thursday after updating Tracleer label. Market ... - New Ratings

UPDATE 3-Actelion 05 profit rises, outlook disappoints  Feb 23, 2006
Actelion, which generates the lion's share of its revenues from sales of Tracleer, a drug that treats pulmonary arterial hypertension (PAH), said total ... - Reuters

European Technology Stocks Fall; ASML Slides, Vodafone Advances  Mar 3, 2006
Actelion Ltd., a Swiss biotechnology company, increased 4.5 percent to 113 Swiss francs on optimism that sales of the company's Tracleer medicine won't be hurt ... - Bloomberg

European Stocks Climb; Adecco, BP, Publicis Shares Pace Gains  Mar 3, 2006
...company, climbed 5.8 percent to 114.4 Swiss francs, the biggest gain in the Stoxx 600, on optimism that sales of the company's Tracleer medicine won't be hurt ... - Bloomberg

Actelion FY sales beat consensus but earnings miss  Feb 22, 2006
Sales of the Swiss company's biggest product, pulmonary arterial hypertension drug Tracleer, were better than expected, up 41 pct to 633.2 mln sfr against ... - Forbes

Credit Suisse Cuts Actelion Target To CHF140  Feb 24, 2006
Higher spending is a sign the company will further leverage its flagship drug Tracleer's considerable leading position, with the rival drug Thelin from ... - New Ratings

WestLB Lifts Actelion's Target  Feb 24, 2006
Adds the analyst conference confirmed views that Tracleer will continue to perform well in '06, sees more than CHF1B in group sales by '09, despite increasing ... - New Ratings

Lehman Lifts Actelion Target To CHF142  Feb 24, 2006
1628 GMT [Dow Jones]--Lehman Brothers lifts Actelion target to CHF142 from CHF135 after raising estimates for sales of company's main drug, Tracleer, in wake ... - New Ratings

Actelion Top-Line Growth Surprises  Feb 23, 2006
0749 GMT [Dow Jones] Actelion's (ATLN.EB) full year '05 sales surprise with better-than-expected growth, especially for its flagship drug Tracleer, says analyst ... - New Ratings

Actelion Shr Price Reaction Overdone -ZKB  Mar 2, 2006
ATLN.EB) share price reaction, closing -5.4% at CHF108.10, was overdone after US FDA asked for a labeling change of its flagship drug Tracleer to include info ... - New Ratings

WestLB Cuts Actelion To Hold Vs Buy >ATLN.EB  Feb 23, 2006
In addition, WestLB argues that newsflow on potential competition for Actelion's flagship drug, Tracleer, is becoming more-and-more visible, in turn pressuring ... - New Ratings

Stakeholder Perspectives: Pulmonary Arterial Hypertension - A ...  Jan 31, 2006
Actelion's Tracleer, the first oral therapy approved by the FDA in 2001, will come under significant competitive pressure over the next three years. ... - Pharmaceutical Business Review

Stakeholder Perspectives: Pulmonary Arterial Hypertension - A ...  Jan 31, 2006
Actelion's Tracleer, the first oral therapy approved by the FDA in 2001, will come under significant competitive pressure over the next three years. ... - Pharmaceutical Business Review

Bear Stearns Resumes Actelion At Peer Perform  Jan 27, 2006
Earnings growth until '08 looks secure, says Bear Stearns, with Myogen's (MYOG) Ambrisentan looking a serious competitor to Actelion's Tracleer from then on. ... - New Ratings

Roche, Actelion To Benefit From Lupus  Jan 12, 2006
For Actelion, increasing the penetration rate of Tracleer 1% "to mimic the impact a larger PAH patient population" would already increase the value of the ... - New Ratings